Koers Sawai Pharmaceutical Co., Ltd. Japan Exchange
Aandelen
4555
JP3323050009
Farmaceutische producten
Omzet 2024 * | 194 mld. 1,24 mld. 1,15 mld. | Omzet 2025 * | 203 mld. 1,3 mld. 1,21 mld. | Marktkapitalisatie | 254 mld. 1,63 mld. 1,51 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 19,79 mld. 127 mln. 118 mln. | Nettowinst (verlies) 2025 * | 19,91 mld. 128 mln. 119 mln. | EV/omzet 2024 * | 1,49 x |
Nettoschuld 2024 * | 34,69 mld. 223 mln. 207 mln. | Nettoschuld 2025 * | 39,72 mld. 255 mln. 237 mln. | EV/omzet 2025 * | 1,45 x |
K/w-verhouding 2024 * |
12,9
x | K/w-verhouding 2025 * |
12,7
x | Werknemers | 3.393 |
Dividendrendement 2024 * |
2,24% | Dividendrendement 2025 * |
2,37% | Vrij verhandelbaar | 0% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 01-04-21 |
President | 66 | 01-04-21 | |
Toru Terashima
BRD | Director/Board Member | 64 | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 01-04-21 |
Kenzo Sawai
BRD | Director/Board Member | 56 | 01-04-21 |
Masatoshi Ohara
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |